Selected article for: "clinical improvement and disease severity"

Title: 2015 ACVIM Forum Research Abstract Program
  • Document date: 2015_5_27
  • ID: 3pnuj5ru_771
    Snippet: Pilot data showed maropitant reduced clinical signs based on client surveys (mild improvement: 3/7, marked improvement: 4/7) and significantly decreased VAS scores (P = 0.002). No difference in BALF % neutrophils or % eosinophils were noted with treatment (P = 0.165, P = 0.710). Subjective clinical improvement could reflect antitussive properties of maropitant or a placebo effect. Preliminary results suggest a lack of reduction of airway inflamma.....
    Document: Pilot data showed maropitant reduced clinical signs based on client surveys (mild improvement: 3/7, marked improvement: 4/7) and significantly decreased VAS scores (P = 0.002). No difference in BALF % neutrophils or % eosinophils were noted with treatment (P = 0.165, P = 0.710). Subjective clinical improvement could reflect antitussive properties of maropitant or a placebo effect. Preliminary results suggest a lack of reduction of airway inflammation, making maropitant unsuitable for treatment of canine CB. Stent placement has been shown to decrease clinical signs and improve quality of life in dogs with tracheal collapse when medical management fails. Stent fractures occasionally occur which complicates post-operative care, raises cost, and decreases operator and owner satisfaction. Coughing likely plays a causative role but variations in clinical signs, disease severity, and operator preferences makes comparing stents based on clinical outcomes problematic. The aim of this study was to evaluate the fatigue properties of two types of tracheal stents in a controlled environment that simulated chronic coughing.

    Search related documents:
    Co phrase search for related documents
    • airway inflammation and causative role: 1, 2
    • airway inflammation and clinical improvement: 1, 2, 3
    • airway inflammation and clinical outcome: 1, 2, 3, 4, 5
    • airway inflammation and disease severity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • airway inflammation and eosinophil BALF neutrophil: 1
    • airway inflammation and life quality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • airway inflammation and medical management: 1
    • airway inflammation and placebo effect: 1
    • airway inflammation and study aim: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • airway inflammation reduction and BALF neutrophil: 1
    • airway inflammation reduction and eosinophil BALF neutrophil: 1